News Oncology Large biopharma Emerging biopharma Academia CROs Clinical trial units MedTech oomnia CTMS oomnia eCOA oomnia eConsent oomnia EDC oomnia ePRO oomnia eSource oomnia eTMF oomnia RTSM
Making oncology data work: Wemedoo’s latest scientific contribution!
Our founder, Dr. Nikola Cihoric, with an interdisciplinary team from Insel Gruppe, Kantonsspital St.Gallen, and international collaborators, published a new paper: A CDE-based data structure for radiotherapeutic decision-making in breast cancer.
It covers 46 data points across 31 criteria, capturing 70% of ASTRO guidelines.
To support interoperability, the data model was designed to be both machine-readable and easy to implement across systems, ensuring that critical clinical information can be shared and applied consistently in real-world settings.
This research marks a key step toward clinical decision support that’s usable: practical, AI-ready, and grounded in how care happens in real life.
Proud to see Wemedoo at the heart of it.
Read the full publication: https://link.springer.com/article/10.1186/s12911-025-03036-1
June 8, 2026
Wemedoo featured in MIT Technology Review (Germany)
Company News
February 26, 2026
Fast database lock in a complex Phase III diabetes study
Company News
February 2, 2026
A new scientific publication featuring Wemedoo researchers has been published in BMC Medical Research Methodology
Company News